About BioNTech Australia
BioNTech Australia was established in December 2023 to build a research and development (R&D) laboratory and clinical GMP mRNA manufacturing facility at La Trobe University’s Bundoora campus in Melbourne. An Innovation Centre has been established in Melbourne that leverages BioNTech’s mRNA expertise to support the Australasian ecosystem in translating research from concept to clinical applications. Additionally, BioNTech’s clinical trial footprint in Australia is progressing multiple investigational cancer therapies for indications with high unmet medical need. The Victorian Government through mRNA Victoria is a strategic partner of BioNTech advancing innovative mRNA research and development within the Australasian ecosystem.
Annual report
In 2024, BioNTech achieved significant progress, with priority programs progressing into late-stage development and enhanced AI capabilities. Access our annual report for the year 2024 for insights into corporate and scientific milestones, comprehensive pipeline updates and a summary of our financial results.
Download the 2024 annual report
15 MB / PDF
Explore more about BioNTech
Our board members
Meet the leaders driving our efforts to leverage the immune system to develop treatments for diseases with unmet and/or high medical need.
Our collaborators
Discover how our partnerships and collaborations with a number of the world’s most established biotechnology and pharmaceutical companies, academia and non-profit organizations help us drive medical breakthroughs and therapeutic innovations to improve standard of care.
Our sites and subsidiaries
BioNTech’s global site network integrates capabilities from discovery to delivery that fuel the research, development and commercialization of novel immunotherapies and vaccines.
Our corporate sustainability and responsibility
Find out how BioNTech’s commitment to innovation, transparency, and sustainability supports global health and responsible governance.
